Tirth Raj

The aim of present study was to design and development of a proniosomal transdermal drug delivery system of lornoxicam for the treatment of rheumatoid arthritis and enhanced skin targeting effect, sustained & prolonged drug release, enhanced skin bioavailability by using different type of non ionic surfactant & cholesterol. Proniosomes of Lornoxicam were prepared by coacervation-phase separation method. The formulation systems were characterized in vitro for size, vesicle count, drug entrapment, drug release profile and vesicular stability. The method used for preparing proniosome resulted in an encapsulation yield of 67.71-87.64%. Proniosomes were characterized by transmission electron microscopy. In vitro studies showed prolonged release of entrapped lornoxicam. A successful attempt was made to develop proniosomal gel for transdermal delivery of lornoxicam using different grades of nonionic surfactant.

The aim of present study,  To formulate and characterized  proniosome contain flurbiprofen in a gel formulation for the treatment of rheumatoid arthritis and enhanced skin targeted effect, sustained & prolonged drug release, enhanced skin bioavailability by using different type of non ionic surfactant & cholesterol. The batches were designed using Box Behnken Design and prepared by coacervation phase separation method. Optimized formulation (PNGopt) showed drug entrapment efficiency of 74.46% and particle size 215nm. In-vitro drug release from PNGopt was found to be 84.15 in 24 hrs. The In-vitro drug release was best explained by zero order kinetics as the plot showed highest linearity and release was governed by Quasi Fickian diffusion.

Oral drug delivery has been known for decades as the most widely utilized route of administration among all the routes. United State Food and Drug Administration (FDA) defined ODT as “a solid dosage form containing medicinal substance or active ingredients which disintegrate rapidly usually within a matter of second when placed upon the tongue. Propranolol is a nonselective beta-adrenergic blocker and is almost completely absorbed following oral administration. However , most of drug is undergoes high first-pass metabolism by the liver and on average, only about 25% of propranolol reaches the systemic circulation. The present study investigated to development of novel fast dissolving tablet of Propranolol HCL which was by first pass metabolism, provide rapid onset of action and increasing the bioavailability of the drug. The fast dissolving tablets were prepared by Direct compression method by using different superdisintegrant like Crosspovidone, crosscarmellose sodium, sodium starch glycolate etc. The advantage of this formulation is such that in case of hypertension attack patient can take the drug without the usage of water. Therefore the main objective of the present work is to develop orodispersible tablets of Propranolol hydrochloride to improve bioavailability, disintegration time, dissolution efficacy and patient compliance.

Tablet is the most popular dosage form of all existing dosage forms , but in some cases due to the large size of dosage forms, in case of uncooperative, pediatric and dysphasia patients, it may create  problems, to overcome this , a new form of dosage form is developed, which is known as fast dissolving tablets or mouth dissolving tablets. These dosage forms are also used to attain instant higher concentration of drug in body for immediate actions. Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). Fenugreek seed powder was added to this formuation because of  its various pharmacological benefits as well as its self disintegrating property. Mouth dissolving tablets were prepared using direct compression method .Formulations were optimized to develop tablets having minimum possible disintegration time. Tablets were evaluated for hardness, weight variation, friability, wetting time, disintegration time and stability. The main objective of the present research is formulation and evaluation  of mouth dissolving tablets of gliclazide which is an antidiabetic drug ,containing fenugreek seed powder as disintegrating agent.

The colon drug delivery system has gained recent importance in delivery of the drug to the colon. These system facilitate the delivery of the drug to the colon and mainly releases the drug in the colonic environment and thereby reduces various side effects of conventional dosage forms like lower dose is required and hence lowering the side effects caused by higher doses. In the present study natural polysaccharide approach is employed and sesbania gum powder was used as a carrier for delivery of the drug to the colon . Satranidazole was selected as a drug of choice because it is most potent nitroimidazole derivative and clinically useful against common protozoa, it is twice as effective as other nitroimidazoles against amoebiasis. Colon targeted tablet of satranidazole can maintain minimum inhibitory concentration for desired duration in fewer doses with fewer side effects. The aim of the present research work is to develop core tablets of satranidazole and compression coated with different ratios of sesbania gum powder. All the formulations were then subjected for evaluation and were tested for hardness, drug content uniformity an in vitro drug release studies. The compression coated formulation CCS 2 released less than 5% of satranidazole drug in the physiological environment of stomach and intestine, when the dissolution studies was further continued in simulated colonic fluids the compression coated tablets with 150mg of sesbania gum powder released another 70% of satranidazole in the colon after degradation by colonic bacteria at the end of 12 hrs.

The proniosomal approach helps to solve the problem regarding stability and provides higher entrapment efficiency over conventional system. Proniosomal gel is a liquid crystalline- compact niosomal hybrid which is prepared by dissolving surfactant in small amount of suitable solvent and least amount of aqueous phase. This compact gel can be converted to niosomes hydration. Proniosomes can entrap hydrophilic as well as lipophillic drugs. Proniosomal gel offers a versatile vesicle drug delivery concept with potential for drug delivery via transdermal rout. Over the last few years an inclusive research has been done over pro-vesicular approach for transdermal drug delivery. Skin has a very tough diffusion barrier inhibiting penetration of drug moiety which is rate limiting barrier for penetration of drugs. There are several approaches that deal with penetration enhancement across the skin. Vesicular and provesicular systems are promising amongst them. Vesicular systems including (niosomes, ethosomes, transfersomes and liposomes) are promising systems to cross this permeation barrier.

Over the last few years an inclusive research has been done over provesicular approach for transdermal drug delivery. Skin has a very tough diffusion barrier inhibiting penetration of drug moiety which is rate limiting barrier for penetration of drugs. There are several approaches that deal with penetration enhancement across the skin. Vesicular and provesicular systems are promising amongst them. Vesicular systems including (niosomes, ethosomes, transfersomes and liposomes) are promising systems to cross this permeation barrier. The proniosomal approach helps to solve the problem regarding stability and provides higher entrapment efficiency over conventional system. Proniosomal gel is a liquid crystalline- compact niosomal hybrid which is prepared by dissolving surfactant in small amount of suitable solvent and least amount of aqueous phase. This compact gel can be converted to niosomes hydration. Proniosomes can entrap hydrophilic as well as lipophillic drugs. Proniosomal gel offers a versatile vesicle drug delivery concept with potential for drug delivery via transdermal rout.